- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01890798
Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol
March 20, 2014 updated by: GlaxoSmithKline
A Continued Access Protocol for Eligible US Subjects With Duchenne Muscular Dystrophy Who Previously Participated in an Approved Drisapersen Study
This is a single arm, open-label continued access protocol of drisapersen for the treatment of male subjects with Duchenne muscular dystrophy (DMD) having dystrophin mutations correctable by drisapersen-induced DMD Exon 51 skipping.
The purpose of this continued access protocol is to offer pre-approval access to drisapersen for the treatment of subjects with DMD who previously participated in eligible drisapersen studies.
The protocol will collect safety data required to assure subject safety and periodic efficacy data on muscle function.
Study Overview
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Prior DMD114876 subjects: Subjects who completed both the 24 week double-blind treatment and 24 week post-treatment phases in study DMD114876, OR Subjects who withdrew from the treatment portion of study DMD114876 due to meeting laboratory safety stopping criteria may be eligible to enroll in the extension study if: the laboratory parameters that led to stopping have resolved; benefit of further treatment with drisapersen outweighs the risk to the individual subject; and following consultation with the GSK Medical Lead.
- Prior DMD115501 subjects:
- Active subjects who entered into open-label extension study DMD115501. Subjects are required to be withdrawn from DMD115501 to participate.
- Prior DMD114044 Subjects: US citizens who completed study DMD114044 in another country and who want to return to the US to participate, upon agreement by a physician conducting this protocol, OR Unites States citizens who participated in DMD114044 but who had to withdraw from the study due to meeting laboratory safety stopping criteria may be eligible to enroll if: the laboratory parameters that led to stopping have resolved; benefit of further treatment with drisapersen outweighs the risk to the individual subject; and following consultation with the GSK Medical Lead and upon agreement of physician conducting this protocol
- Prior DMD114349 Subjects: US citizens who participated in and completed study DMD114044 in another country and who entered into the ongoing open-label extension study DMD114349 in a country outside the US who wish to withdraw from DMD114349 and return to the US to participate in this protocol, upon agreement by a physician conducting this protocol. Subjects are required to withdraw from DMD114349 to participate in this protocol.
- Baseline platelets of 150 x 109/Liters (L) or greater and no history of thrombocytopenia.
- Continued use of glucocorticosteroids for a minimum of 60 days prior to protocol entry with a reasonable expectation that the subject will remain on steroids for the duration of the protocol. Changes to or cessation of glucocorticosteroids will be at the discretion of the physician conducting this protocol in consultation with the subject/parent. The GSK Medical Lead must be notified in a timely manner.
- Willing and able to comply with all protocol requirements and procedures (with the exception of those assessments requiring a subject to be ambulant, for those subjects who have lost ambulation).
- Able to give informed assent and/or consent in writing signed by the subject and/or parent(s)/legal guardian (according to local regulations).
Exclusion Criteria:
- Subject had a serious adverse experience or who met safety stopping criteria that remains unresolved from protocol DMD114876, which in the opinion of the physician conducting this protocol could have been attributable to study medication, and which is ongoing. Once resolved, subject may be eligible to enroll following consultation with the GlaxoSmithKline (GSK) Medical Lead.
- Use of anticoagulants, antithrombotics or antiplatelet agents, or previous treatment with investigational drugs, except for drisapersen, within 28 days of the first administration of drisapersen.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Drisapersen (DMD117402)
The protocol is open only to the subjects who completed GSK protocol DMD114876 and participated in protocol DMD115501, United States citizens who have completed protocol DMD114044, or United States citizens who are participating in protocol DMD114349 outside the United States and want to end their participation in the DMD114349 study.
Eligible subjects will receive drisapersen 6 milligram (mg)/kilograms (kg) once a week via subcutaneous (SC) injection.
|
Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection.
The strength of drisapersen solution will be 200 mg/mL.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as assessed by the collection of adverse events (AEs)
Time Frame: Baseline to Week 48
|
AEs will be collected from the start of Study Treatment and until 5 days post last-dose (at follow up).
|
Baseline to Week 48
|
Safety as assessed by laboratory parameters
Time Frame: Baseline to Week 48
|
Absolute values and changes over time of hematology, clinical chemistry, and urinalysis
|
Baseline to Week 48
|
Safety as assesses by electrocardiogram (ECG) intervals
Time Frame: Baseline to Week 48
|
Baseline to Week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Actual)
January 1, 2014
Study Completion (Anticipated)
July 1, 2015
Study Registration Dates
First Submitted
June 27, 2013
First Submitted That Met QC Criteria
June 27, 2013
First Posted (Estimate)
July 2, 2013
Study Record Updates
Last Update Posted (Estimate)
March 24, 2014
Last Update Submitted That Met QC Criteria
March 20, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 117402
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscular Dystrophies
-
Assistance Publique - Hôpitaux de ParisRecruitingLimb Girdle Muscular DystrophiesFrance
-
aTyr Pharma, Inc.CompletedLimb-Girdle Muscular Dystrophies | Facioscapulohumeral Muscular DystrophyUnited States, Denmark, France
-
Wake Forest University Health SciencesMuscular Dystrophy AssociationCompletedMuscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)United States
-
Virginia Commonwealth UniversityWashington University School of Medicine; University of Iowa; University of Minnesota and other collaboratorsRecruitingMuscular Dystrophies | Limb Girdle Muscular DystrophyUnited States, United Kingdom
-
Sarepta Therapeutics, Inc.Active, not recruiting
-
ML Bio Solutions, Inc.Virginia Commonwealth UniversityCompletedMuscular Dystrophies | Limb Girdle Muscular DystrophyUnited States, Denmark
-
Neurogen Brain and Spine InstituteWithdrawn
-
Rigshospitalet, DenmarkRecruitingLimb Girdle Muscular DystrophyDenmark
-
Rigshospitalet, DenmarkFunding: Toyota Foundation; Funding: Hede Nielsen Foundation; Funding: Grosserer... and other collaboratorsActive, not recruiting
-
GenethonActive, not recruitingLGMD2IDenmark, France, United Kingdom
Clinical Trials on Drisapersen
-
BioMarin PharmaceuticalNo longer availableDuchenne Muscular DystrophyUnited States, Germany, United Kingdom, Japan, Netherlands, France, Spain, Korea, Republic of, Italy, Belgium, Taiwan, Argentina, Australia, Bulgaria, Czechia, Israel, Norway, Poland, Russian Federation, Turkey
-
BioMarin PharmaceuticalTerminated
-
BioMarin PharmaceuticalTerminatedMuscular DystrophiesUnited States, Canada